Phase 2 N=58 NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
Rectal Cancer
Primary: Percentage of Organ Preservation — 57 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=39 Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
Colon Cancer · Rectal Cancer
Primary: Incidence of Complete Resection — 13 participants
Phase 2 N=146 Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer
Colorectal Cancer
Primary: Pathologic Complete Response Rate — 10.4; 20.8 percentage of participants
N/A N=150 Ploidy and Stroma in Early Rectal Cancer
Rectal Cancer
Primary: Correlation Between Ploidy Status With Local Recurrence of Cancer — 3; 31; 14; 92 Participants
Phase 2 N=25 Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer
Rectal Cancer
Primary: Pathologic Local Tumor Response — 8; 6; 11 Participants
Phase 2 N=27 Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer
Colorectal Cancer
Primary: Pathologic Response and Complete Response — 3 Participants
Phase 2 N=45 Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
Epidermoid Carcinoma · Anus
Primary: Percentage of Patients With Complete Response to Treatment — 30; 10; 0; 4 Participants
Phase 2 N=135 Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Rectal Carcinoma
Primary: Rate of Tumor Downstaging Compared With Historical Controls. — 64.4; 64.5 percentage of participants
Phase 2 N=20 Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
Cancer of Rectum · Cancer of the Rectum · Neoplasm, Rectum
Primary: Complete Response Rate — 12 Participants
Phase 2 N=124 Tecemotide (L-BLP25) in Rectal Cancer
Rectal Cancer
Primary: Change From Baseline in Tumor Immune Response Evaluated by Immunohistochemical (IHC) Analysis of Tumor Infiltrating Lymphocytes (TILs) at Week 14 (Post-surgery) — 0.609…
Phase 2 N=84 Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer
Locally Advanced Rectal Cancer
Primary: Pathologic Response at Surgery. Overview of Complete Pathologic Responses, Good and Little Tumour Regression Rates at Surgery. — 34; 11; 41; 24 percentage of cases
N/A N=15 PET-MRI in Diagnosing Patients With Colon or Rectal Cancer
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IIA Colon Cancer
Primary: Maximum Standardized Uptake Value (SUVmax) in Physiologic Regions and Fluorodeoxyglucose (FDG) Avid Lesions in Participants Where PET-CT Was Performed Prior to the…
N/A N=63 Non-Operative Management and Early Response Assessment in Rectal Cancer
Adenocarcinoma of the Lower Rectum
Primary: Clinical Complete Response Rate — 36; 2 Participants
Phase 1 N=22 Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer
Rectal Cancer
Primary: Maximum Tolerated Dose (MTD) — 0; 0; 0 mg/m^2
Phase 1 N=13 Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer
Rectal Cancer
Primary: The Number of Participants Experiencing Dose Limiting Toxicities (DLT) — 0; 0; 0 Participants
Phase 2 N=37 A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.
Rectal Neoplasms
Primary: Feasibility of Pemetrexed Prior to Surgery — 33; 4 participants
N/A N=20 Patient-Derived Organoids for Rectal Cancer
Rectum Cancer
Primary: Number of Participants With Biopsies That Form Spherical Organoids — 14 Participants
Phase 2 N=9 Chemoradiation or Brachytherapy for Rectal Cancer
Rectal Cancer
Primary: Number of Patients With Pathologic Complete Response — 0; 2 Participants
N/A N=269 Complete Histologic Resection of Adenomatous Polyps?
Adenomatous Polyps
Primary: Percent of Incompletely Resected Adenomatous Polyps — 10.1 percentage of incomplete resection
Phase 2 N=83 S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer
Colorectal Cancer
Primary: Pathologic Complete Response Rate — 25 percentage of participants — p=0.18
Phase 2 N=139 Pre-op Rectal ChemoRad +/- Cetuximab
Rectal Cancer
Primary: Percentage of Pathologic Response Rate (pCR) With 95% Confidence Interval. — 26.6; 26.7 percentage of participants
Phase 2 N=39 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
Rectal Cancer
Primary: Pathologic Complete Response Rate — 7 participants
Phase 3 N=486 Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
Colorectal Cancer
Primary: Comparing Laparoscopic-assisted Resection to Open Rectal Resection for Rectal Cancer as Measured by the Percentage of Patients With Successful Resection Based on…
Phase 2 N=180 Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer
Rectal Cancer
Primary: Number of Patients Achieving Pathologic Complete Response (pCR). — 25; 9; 90; 56 Participants
Phase 2 N=53 Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy
Ulcerative Colitis
Primary: Detected Intraepithelial Neoplasia — 0.2 Number of detected IN
Phase 2 N=91 A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer
Rectal Cancer
Primary: Percentage of Participants With Tumor Sterilization Defined by ypT0-N0 — 23.8; 11.4 percentage of participants — p=0.015
N/A N=35 Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer
Colorectal Cancer
Primary: Complete Pathologic Response — 8; 21; 1 participants
Phase 2 N=66 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
Rectal Cancer · Cancer of the Rectum · Colorectal Cancer
Primary: Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment…
Phase 2 N=79 Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer
Colorectal Cancer
Primary: The Percentage of Patients Experiencing Treatment-related Gastrointestinal Adverse Events ≥ Grade 2 Per National Cancer Institute (NCI) Common Terminology Criteria for…
N/A N=57 Study of the Preservation of the Left Colic Artery on Rectum Cancer Surgery
Rectum Cancer
Primary: The Blood Pressure of the Arterial Arcade — 42.31; 48.50 mmHg